Ceryvyn Therapeutics Company Description

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.

The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).

It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026.

Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Ceryvyn Therapeutics Limited

Country	Australia
Founded	1984
Industry	Biotechnology
Sector	Healthcare
Employees	33
CEO	Jeremy Levin

Contact Details

Address: Level 9 Melbourne, VIC 3000 Australia
Phone	61 3 9826 0399
Website	ceryvyn.com

Stock Details

Ticker Symbol	CYV
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000478117
SIC Code	2836

Key Executives

Name	Position
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.	Chief Executive Officer and Chairperson
Hamish George	Chief Financial Officer and Joint Company Secretary
Dr. Stuart Mudge	Chief Operating Officer
Dr. Michael Gerometta Ph.D.	Chief Technology Officer
Stephanie Vipond	Joint Company Secretary